A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight

NCT06824051 · Completed

Last updated 2026-05-28

This clinical trial is testing the medication Orforglipron (LY3502970) in adults who have obesity or are overweight to see how it affects visceral fat.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 120 people

Who can join Ages 18+ · all sexes

Timeline Started 2025-02 · est. completion 2026-01

Where 4 sites · United States

What this study is testing ClinicalTrials.gov NCT06824051 ↗

Description as written by the study sponsor.

The main purpose of this study is to see how orforglipron affects the amount of body fat compared with placebo in participants with obesity or overweight. Participation in the study will last approximately 8 months.

Treatments tested

Orforglipron also known as LY3502970 Drug

Administered orally
Placebo Drug

Administered orally

Main thing measured	Percent Change from Baseline in Visceral Adipose Tissue (VAT)
Sponsor	Eli Lilly and Company
Conditions studied	Obesity, Overweight
GLP-1 drugs	orforglipron

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06824051 ↗